 Shares of Luminex Corp. gained 10.8 in premarket trading on Monday after the company said its COVID-19 antibody test had received an emergency use authorization from the Food and Drug Administration. This is the third coronavirus test developed by Luminex during the pandemic; this particular test received about 640,000 in federal funding from U.S. health agencies. Antibody tests are not diagnostic tests. They do not identify current infections with the virus but can indicate whether someone contracted it in the past or has been recently exposed to someone with the virus. Luminexs stock has jumped 56.6 year-to-date, while the SP 500 is 0.2. 